RGNX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- 0.26
- P/B
- 25.34
- P/S (TTM)
- 6.08
- EV/EBITDA
- -3.37
Profitability & growth
- ROE (TTM)
- -196.4%
- Operating margin
- -1304.0%
- Revenue growth YoY
- -92.8%
- Dividend yield
- —
- Beta
- 0.90
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Regenxbio Inc
Company profileREGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
